sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.
|
alprazolam
|
fluvoxamine
|
EFFECT
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s24
|
DDI-DrugBank.d76.s24.p0
|
Ketamine: Marked hypertension and tachycardia have been reported in association with concomitant administration of levothyroxine sodium and ketamine.
|
levothyroxine sodium
|
ketamine
|
EFFECT
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s13
|
DDI-DrugBank.d411.s13.p2
|
Increased nephrotoxicity has been reported following concomitant administration of cephalosporins and aminoglycoside antibiotics.
|
cephalosporins
|
aminoglycoside antibiotics
|
EFFECT
|
Cefotaxime_ddi.xml
|
DDI-DrugBank.d100.s0
|
DDI-DrugBank.d100.s0.p0
|
Total body clearance of Simulect was reduced by an average 22% and 51% when azathioprine and mycophenolate mofetil, respectively, were added to a regimen consisting of cyclosporine, USP (MODIFIED) and corticosteroids.
|
mycophenolate mofetil
|
corticosteroids
|
NONE
|
Basiliximab_ddi.xml
|
DDI-DrugBank.d544.s3
|
DDI-DrugBank.d544.s3.p8
|
Potassium Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.
|
Fosinopril sodium
|
thiazide diuretics
|
EFFECT
|
Fosinopril_ddi.xml
|
DDI-DrugBank.d176.s3
|
DDI-DrugBank.d176.s3.p5
|
The safety and efficacy of concomitant use of REVIA and disulfiram is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.
|
REVIA
|
disulfiram
|
EFFECT
|
Naltrexone_ddi.xml
|
DDI-DrugBank.d346.s2
|
DDI-DrugBank.d346.s2.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
acetaminophen
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p0
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
fenoprofen
|
oxolinic acid
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p903
|
therefore, it is theoretically possible that lansoprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. ketoconazole, ampicillin esters, iron salts, digoxin).
|
lansoprazole
|
iron
|
MECHANISM
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s12
|
DDI-DrugBank.d431.s12.p2
|
Concomitant use of calcium supplements and L-lysine may increase calcium absorption
|
calcium
|
L-lysine
|
MECHANISM
|
L-Lysine_ddi.xml
|
DDI-DrugBank.d344.s0
|
DDI-DrugBank.d344.s0.p0
|
Drugs that reduce the number of blood platelets by causing bone marrow depression (such as antineoplastic agents) or drugs which inhibit platelet function (eg, aspirin and other non-steroidal anti-inflammatory drugs, dipyridamole, hydrochloroquine, clofibrate, dextran) may increase the bleeding tendency produced by anticoagulants without altering prothrombin time determinations.
|
hydrochloroquine
|
anticoagulants
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s90
|
DDI-DrugBank.d64.s90.p24
|
Amitriptyline: Concurrent administration of 25 mg or 100 mg cinacalcet with 50 mg amitriptyline increased amitriptyline exposure and nortriptyline (active metabolite) exposure by approximately 20% in CYP2D6 extensive metabolizers.
|
cinacalcet
|
amitriptyline
|
MECHANISM
|
Cinacalcet_ddi.xml
|
DDI-DrugBank.d512.s3
|
DDI-DrugBank.d512.s3.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
Gris-PEG
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p13
|
Corticosteroids: Concomitant administration with aspirin may increase the risk of gastrointestinal ulceration and may reduce serum salicylate levels.
|
Corticosteroids
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s2
|
DDI-DrugBank.d443.s2.p0
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
cisapride
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p45
|
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired
|
Bezalip
|
cholestryramine
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s9
|
DDI-DrugBank.d291.s9.p2
|
THE POTENTIATING ACTION OF HYDROXYZINE MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH CENTRAL NERVOUS SYSTEM DEPRESSANTS SUCH AS NARCOTICS, NON-NARCOTIC ANALGESICS AND BARBITURATES.
|
HYDROXYZINE
|
NARCOTICS
|
EFFECT
|
Hydroxyzine_ddi.xml
|
DDI-DrugBank.d308.s0
|
DDI-DrugBank.d308.s0.p1
|
The concomitant administration of rifampin and warfarin resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect.
|
warfarin
|
warfarin
|
NONE
|
1115445.xml
|
DDI-MedLine.d116.s3
|
DDI-MedLine.d116.s3.p2
|
In rheumatoid arthritis, concomitant medications besides MTX were nonsteroidal anti-inflammatory agents, folic acid, corticosteroids and/or narcotics.
|
MTX
|
corticosteroids
|
NONE
|
Infliximab_ddi.xml
|
DDI-DrugBank.d45.s4
|
DDI-DrugBank.d45.s4.p2
|
Phenytoin: Serum phenytoin levels may be increased by aspirin.
|
phenytoin
|
aspirin
|
EFFECT
|
Aspirin_ddi.xml
|
DDI-DrugBank.d443.s7
|
DDI-DrugBank.d443.s7.p2
|
Morphine prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by ADL 8-2698 (P = .004).
|
Morphine
|
ADL 8-2698
|
EFFECT
|
11180040.xml
|
DDI-MedLine.d87.s4
|
DDI-MedLine.d87.s4.p0
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
Antiarrhythmics
|
ergot derivatives
|
NONE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p18
|
Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, cyclosporine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, or ergot alkaloids (ergotamine, dihydroergotamine) should be administered with caution in patients receiving SPRYCEL.
|
tacrolimus
|
SPRYCEL
|
ADVISE
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s15
|
DDI-DrugBank.d48.s15.p84
|
Isoflurane or enflurane administered with nitrous oxide/oxygen to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of NIMBEX and decrease the required infusion rate of NIMBEX.
|
Isoflurane
|
NIMBEX
|
EFFECT
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s6
|
DDI-DrugBank.d60.s6.p3
|
Probenecid : Probenecid is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, theophylline, and zidovudine).
|
acyclovir
|
famotidine
|
NONE
|
Cidofovir_ddi.xml
|
DDI-DrugBank.d260.s0
|
DDI-DrugBank.d260.s0.p49
|
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
|
tricyclic antidepressants
|
CMI
|
EFFECT
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s4
|
DDI-DrugBank.d238.s4.p2
|
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
|
benzodiazepines
|
cimetidine
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s8
|
DDI-DrugBank.d338.s8.p2
|
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.
|
nitroglycerin
|
INOmax
|
EFFECT
|
Nitric Oxide_ddi.xml
|
DDI-DrugBank.d183.s2
|
DDI-DrugBank.d183.s2.p5
|
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)
|
barbiturates
|
tetracyclines
|
NONE
|
Desogestrel_ddi.xml
|
DDI-DrugBank.d285.s1
|
DDI-DrugBank.d285.s1.p4
|
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
|
TCAs
|
SSRIs
|
ADVISE
|
Clomipramine_ddi.xml
|
DDI-DrugBank.d238.s19
|
DDI-DrugBank.d238.s19.p0
|
Cimetidine: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.
|
Cimetidine
|
tricyclic antidepressants
|
MECHANISM
|
Doxepin_ddi.xml
|
DDI-DrugBank.d223.s22
|
DDI-DrugBank.d223.s22.p2
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
quinine
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p73
|
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or enalaprilat.
|
diuretics
|
enalapril
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s0
|
DDI-DrugBank.d107.s0.p0
|
When used in therapeutic doses, azithromycin had a modest effect on the pharmacokinetics of atorvastatin, carbamazepine, cetirizine, didanosine, efavirenz, fluconazole, indinavir, midazolam, rifabutin, sildenafil, theophylline (intravenous and oral), triazolam, trimethoprim/sulfamethoxazole or zidovudine.
|
azithromycin
|
rifabutin
|
MECHANISM
|
Azithromycin_ddi.xml
|
DDI-DrugBank.d53.s7
|
DDI-DrugBank.d53.s7.p8
|
- Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
non-steroidal anti-inflammatory agent
|
potassium-sparing diuretics
|
EFFECT
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s19
|
DDI-DrugBank.d46.s19.p5
|
Certain drugs, including nonsteroidal anti-inflammatory agents (NSAIDs), salicylates, monoamine oxidase inhibitors, and non-selective beta-adrenergic-blocking agents may potentiate the hypoglycemic action of Starlix and other oral antidiabetic drugs.
|
NSAIDs
|
Starlix
|
EFFECT
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s14
|
DDI-DrugBank.d460.s14.p9
|
In a ten-subject study, coadministration of diltiazem (120 mg bid) with lovastatin resulted in a 3-4 times increase in mean lovastatin AUC and Cmax vs. lovastatin alone;
|
diltiazem
|
lovastatin
|
MECHANISM
|
Diltiazem_ddi.xml
|
DDI-DrugBank.d565.s37
|
DDI-DrugBank.d565.s37.p0
|
Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.
|
Valdecoxib
|
lithium
|
MECHANISM
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s20
|
DDI-DrugBank.d328.s20.p3
|
Nabilone should be administered with caution to patients who are taking other psychoactive drugs or CNS depressants, including alcohol, barbiturates and narcotic analgesics, or to those with a history of psychiatric disorder (including manic-depressive illness and schizophrenia).
|
Nabilone
|
CNS depressants
|
ADVISE
|
Nabilone_ddi.xml
|
DDI-DrugBank.d552.s0
|
DDI-DrugBank.d552.s0.p1
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
allopurinol
|
glucagon
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p125
|
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.
|
Lodine
|
methotrexate
|
MECHANISM
|
Etodolac_ddi.xml
|
DDI-DrugBank.d219.s7
|
DDI-DrugBank.d219.s7.p3
|
Caution is therefore advised when administering PEGANONE to patients receiving coumarin anticoagulants.
|
PEGANONE
|
coumarin anticoagulants
|
ADVISE
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s6
|
DDI-DrugBank.d359.s6.p0
|
Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracyclines in conjunction with penicillin.
|
tetracyclines
|
penicillin
|
ADVISE
|
Doxycycline_ddi.xml
|
DDI-DrugBank.d500.s1
|
DDI-DrugBank.d500.s1.p2
|
Morphine: Combination hormonal contraceptives may increase the clearance of morphine.
|
hormonal contraceptives
|
morphine
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s26
|
DDI-DrugBank.d485.s26.p2
|
These studies indicate that ketoconazole or erythromycin co-administration enhances fexofenadine gastrointestinal absorption.
|
ketoconazole
|
fexofenadine
|
MECHANISM
|
Fexofenadine_ddi.xml
|
DDI-DrugBank.d466.s17
|
DDI-DrugBank.d466.s17.p1
|
Warfarin: Quinolones, including enoxacin, decrease the clearance of R-warfarin, the less active isomer of racemic warfarin.
|
Warfarin
|
enoxacin
|
NONE
|
Enoxacin_ddi.xml
|
DDI-DrugBank.d395.s23
|
DDI-DrugBank.d395.s23.p1
|
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH TRICOR.
|
COUMARIN ANTICOAGULANTS
|
TRICOR
|
ADVISE
|
Fenofibrate_ddi.xml
|
DDI-DrugBank.d283.s0
|
DDI-DrugBank.d283.s0.p2
|
The reduced risk of adverse events and therapeutic superiority compared with haloperidol and risperidone in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
|
haloperidol
|
risperidone
|
NONE
|
11217867.xml
|
DDI-MedLine.d83.s19
|
DDI-MedLine.d83.s19.p0
|
Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and butyrophenone classes of antipsychotic agents, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other anticonvulsant drugs.
|
benzodiazepine class
|
thioxanthene classes of antipsychotic agents
|
EFFECT
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s7
|
DDI-DrugBank.d333.s7.p6
|
Although specific drug interaction studies have not been conducted with ALPHAGAN P, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered.
|
ALPHAGAN P
|
CNS depressants
|
ADVISE
|
Brimonidine_ddi.xml
|
DDI-DrugBank.d138.s0
|
DDI-DrugBank.d138.s0.p0
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
ciprofloxacin
|
calcium
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p15
|
However, concomitant administration of aspirin with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.
|
aspirin
|
CELEBREX
|
EFFECT
|
Celecoxib_ddi.xml
|
DDI-DrugBank.d172.s14
|
DDI-DrugBank.d172.s14.p0
|
Presumably, phenytoin acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.
|
phenytoin
|
coumarin
|
MECHANISM
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s3
|
DDI-DrugBank.d359.s3.p0
|
The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of Fe per kg diet resulted in a decreased renal excretion of cobalt.
|
Fe
|
cobalt
|
MECHANISM
|
7599505.xml
|
DDI-MedLine.d34.s8
|
DDI-MedLine.d34.s8.p1
|
Misonidazole reduced the antitumour activity of oral CCNU by dose modifying factors (DMF) of 0.58-0.71.
|
Misonidazole
|
CCNU
|
EFFECT
|
3966974.xml
|
DDI-MedLine.d85.s7
|
DDI-MedLine.d85.s7.p0
|
The actions of the benzodiazepines may be potentiated by barbiturates, narcotics, phenothiazines, monoamine oxidase inhibitors or other antidepressants.
|
benzodiazepines
|
antidepressants
|
EFFECT
|
Clorazepate_ddi.xml
|
DDI-DrugBank.d335.s3
|
DDI-DrugBank.d335.s3.p4
|
Propranolol attenuated the heart rate increase following administration of immediate release nisoldipine.
|
Propranolol
|
nisoldipine
|
EFFECT
|
Nisoldipine_ddi.xml
|
DDI-DrugBank.d106.s6
|
DDI-DrugBank.d106.s6.p0
|
Interaction on the antinociceptive effect between neurotensin and enkephalins or tuftsin.
|
neurotensin
|
enkephalins
|
EFFECT
|
6545985.xml
|
DDI-MedLine.d131.s0
|
DDI-MedLine.d131.s0.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
felbamate
|
theophylline
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p648
|
Therefore, when chlorothiazide and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained
|
chlorothiazide
|
non-steroidal anti-inflammatory agents
|
ADVISE
|
Chlorothiazide_ddi.xml
|
DDI-DrugBank.d46.s20
|
DDI-DrugBank.d46.s20.p0
|
Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect.
|
Acetazolamide
|
amphetamine
|
MECHANISM
|
Acetazolamide_ddi.xml
|
DDI-DrugBank.d368.s9
|
DDI-DrugBank.d368.s9.p0
|
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.
|
Haloperidol
|
(+)-NANM
|
EFFECT
|
3968644.xml
|
DDI-MedLine.d30.s11
|
DDI-MedLine.d30.s11.p0
|
Sumatriptan: Sumatriptan has been reported to cause coronary artery vasospasm, and its effect could be additive with D.H.E. 45 (dihydroergotamine mesylate) Injection, USP.
|
Sumatriptan
|
dihydroergotamine mesylate
|
EFFECT
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s1
|
DDI-DrugBank.d410.s1.p4
|
Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of cimetidine, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
|
bupropion
|
hydroxybupropion
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s6
|
DDI-DrugBank.d5.s6.p2
|
Cholestyramine-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of vitamin K.
|
cholestyramine
|
vitamin K
|
MECHANISM
|
Menadione_ddi.xml
|
DDI-DrugBank.d139.s3
|
DDI-DrugBank.d139.s3.p3
|
Co-administration of bosentan decreased the plasma concentrations of glyburide by approximately 40%.
|
bosentan
|
glyburide
|
MECHANISM
|
Bosentan_ddi.xml
|
DDI-DrugBank.d289.s19
|
DDI-DrugBank.d289.s19.p0
|
It is possible that the cardiovascular action of other calcium channel blockers could be enhanced by the addition of Nimotop .
|
calcium channel blockers
|
Nimotop
|
EFFECT
|
Nimodipine_ddi.xml
|
DDI-DrugBank.d310.s0
|
DDI-DrugBank.d310.s0.p0
|
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).
|
enalapril
|
diuretics
|
EFFECT
|
Enalapril_ddi.xml
|
DDI-DrugBank.d107.s3
|
DDI-DrugBank.d107.s3.p4
|
Dexbrompheniramine can interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).
|
Dexbrompheniramine
|
anticholinergics
|
INT
|
Dexbrompheniramine_ddi.xml
|
DDI-DrugBank.d62.s0
|
DDI-DrugBank.d62.s0.p3
|
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
|
estazolam
|
phenytoin
|
MECHANISM
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s4
|
DDI-DrugBank.d338.s4.p1
|
The hypotensive effect of sodium nitroprusside is augmented by that of most other hypotensive drugs, including ganglionic blocking agents, negative inotropic agents, and inhaled anesthetics.
|
sodium nitroprusside
|
ganglionic blocking agents
|
EFFECT
|
Nitroprusside_ddi.xml
|
DDI-DrugBank.d394.s0
|
DDI-DrugBank.d394.s0.p1
|
Amitriptyline in combination with clonidine enhances the manifestation of corneal lesions in rats Epidural Injection Clonidine may potentiate the CNS-depressive effect of alcohol, barbiturates or other sedating drugs.
|
Amitriptyline
|
clonidine
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s2
|
DDI-DrugBank.d495.s2.p0
|
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.
|
iron
|
norfloxacin
|
ADVISE
|
Norfloxacin_ddi.xml
|
DDI-DrugBank.d217.s11
|
DDI-DrugBank.d217.s11.p9
|
Care should be taken if labetalol is used concomitantly with calcium antagonists of the verapamil type.
|
calcium antagonist
|
verapamil
|
NONE
|
Labetalol_ddi.xml
|
DDI-DrugBank.d412.s11
|
DDI-DrugBank.d412.s11.p2
|
A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
|
hydantoin antiepileptic
|
phenytoin
|
INT
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s2
|
DDI-DrugBank.d359.s2.p0
|
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.
|
iron
|
FACTIVE
|
ADVISE
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s7
|
DDI-DrugBank.d347.s7.p34
|
The most commonly occurring drug interactions are listed below: - Drugs that may increase plasma phenytoin concentrations include: acute alcohol intake, amiodarone, chboramphenicol, chlordiazepoxide, cimetidine, diazepam, dicumarol, disulfiram, estrogens, ethosuximide, fluoxetine, H2-antagonists, halothane, isoniazid, methylphenidate, phenothiazines, phenylbutazone, salicylates, succinimides, sulfonamides, tolbutamide, trazodone
|
amiodarone
|
H2-antagonists
|
NONE
|
Fosphenytoin_ddi.xml
|
DDI-DrugBank.d40.s10
|
DDI-DrugBank.d40.s10.p49
|
Concomitant administration of Mefloquine and other related compounds (eg, quinine, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.
|
Mefloquine
|
quinine
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s5
|
DDI-DrugBank.d220.s5.p0
|
Paroxetine: Coadministration of a single dose of Sonata 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
|
Paroxetine
|
Sonata
|
NONE
|
Zaleplon_ddi.xml
|
DDI-DrugBank.d324.s6
|
DDI-DrugBank.d324.s6.p0
|
Ketoconazole: When a single 125-mg dose of Aprepitant was administered on Day5 of a 10-day regimen of 400 mg/day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
|
Aprepitant
|
ketoconazole
|
MECHANISM
|
Aprepitant_ddi.xml
|
DDI-DrugBank.d382.s36
|
DDI-DrugBank.d382.s36.p4
|
Veratrum alkaloids: Amphetamines inhibit the hypotensive effect of veratrum alkaloids.
|
Amphetamines
|
veratrum alkaloids
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s24
|
DDI-DrugBank.d158.s24.p2
|
Insulin: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of EXTRANEAL on insulin absorption from the peritoneal cavity or on insulins ability to control blood glucose when insulin was administered intraperitoneally with EXTRANEAL.
|
insulin
|
EXTRANEAL
|
NONE
|
Icodextrin_ddi.xml
|
DDI-DrugBank.d501.s5
|
DDI-DrugBank.d501.s5.p14
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
selegiline hydrochloride
|
fluoxetine
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p16
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
cyclosporin
|
delavirdine
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p405
|
A 21 (17)% decrease in the steady-state AUC of ganciclovir was observed when VIDEX was administered 2 hours prior to ganciclovir, but not when the two drugs were administered simultaneously (n = 12).
|
VIDEX
|
ganciclovir
|
MECHANISM
|
Didanosine_ddi.xml
|
DDI-DrugBank.d43.s7
|
DDI-DrugBank.d43.s7.p2
|
Lithium generally should not be given with diuretics because they reduce its renal clearance and add a high risk of lithium toxicity.
|
Lithium
|
diuretics
|
ADVISE
|
Amiloride_ddi.xml
|
DDI-DrugBank.d356.s2
|
DDI-DrugBank.d356.s2.p0
|
Expected changes in laboratory assessments of PT and INR were observed after warfarin administration, but these changes were not affected by concomitant lenalidomide administration.
|
warfarin
|
lenalidomide
|
NONE
|
Lenalidomide_ddi.xml
|
DDI-DrugBank.d169.s3
|
DDI-DrugBank.d169.s3.p0
|
Adrenergic Agents:Some individuals receiving ZYVOX may experience a reversible enhancement of the pressor response to indirect-acting sympathomimetic agents, vasopressor or dopaminergic agents.
|
ZYVOX
|
sympathomimetic agents
|
EFFECT
|
Linezolid_ddi.xml
|
DDI-DrugBank.d441.s2
|
DDI-DrugBank.d441.s2.p4
|
Tricyclic antidepressants may antagonize the hypotensive effects of clonidine.
|
Tricyclic antidepressants
|
clonidine
|
EFFECT
|
Clonidine_ddi.xml
|
DDI-DrugBank.d495.s4
|
DDI-DrugBank.d495.s4.p0
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
lamotrigine
|
zonisamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p781
|
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram) is clinically warranted, appropriate observation of the patient is advised.
|
sumatriptan
|
fluoxetine
|
ADVISE
|
Escitalopram_ddi.xml
|
DDI-DrugBank.d568.s17
|
DDI-DrugBank.d568.s17.p1
|
Co-administration of CYP3A4 inhibitors (eg, ketoconazole, itraconazole, erythromycin, grapefruit juice, cimetidine) with felodipine may lead to several- fold increases in the plasma levels of felodipine, either due to an increase in bioavailability or due to a decrease in metabolism.
|
ketoconazole
|
itraconazole
|
NONE
|
Felodipine_ddi.xml
|
DDI-DrugBank.d316.s1
|
DDI-DrugBank.d316.s1.p0
|
Because of foscarnets tendency to cause renal impairment, the use of FOSCAVIR should be avoided in combination with potentially nephrotoxic drugs such as aminoglycosides, amphotericin B and intravenous pentamidine unless the potential benefits outweigh the risks to the patient.
|
amphotericin B
|
pentamidine
|
NONE
|
Foscarnet_ddi.xml
|
DDI-DrugBank.d511.s4
|
DDI-DrugBank.d511.s4.p9
|
Therefore, when meclofenamate sodium is given to a patient receiving warfarin, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.
|
meclofenamate sodium
|
warfarin
|
ADVISE
|
Meclofenamic acid_ddi.xml
|
DDI-DrugBank.d113.s1
|
DDI-DrugBank.d113.s1.p0
|
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.
|
diazepam
|
valdecoxib
|
NONE
|
Valdecoxib_ddi.xml
|
DDI-DrugBank.d328.s48
|
DDI-DrugBank.d328.s48.p1
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
azole antifungals
|
valproate
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p72
|
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.
|
isoniazid
|
vincristine
|
NONE
|
Zalcitabine_ddi.xml
|
DDI-DrugBank.d263.s13
|
DDI-DrugBank.d263.s13.p109
|
Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.
|
Aspirin
|
corticosteroids
|
ADVISE
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s25
|
DDI-DrugBank.d314.s25.p0
|
- a sulfa-based drug such as sulfamethoxazole-trimethoprim (Bactrim, Septra), sulfisoxazole (Gantrisin), or sulfasalazine (Azulfidine);
|
sulfasalazine
|
Azulfidine
|
NONE
|
Glimepiride_ddi.xml
|
DDI-DrugBank.d521.s3
|
DDI-DrugBank.d521.s3.p27
|
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent diuretics such as furosemide.
|
cephalosporins
|
furosemide
|
EFFECT
|
Ceftazidime_ddi.xml
|
DDI-DrugBank.d122.s0
|
DDI-DrugBank.d122.s0.p2
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.